Liberum Capital reaffirmed their buy rating on shares of Assura PLC (LON:AGR) in a research report released on Monday morning. They currently have a GBX 68 ($0.90) price objective on the real estate investment trust’s stock.

Separately, Peel Hunt reiterated a hold rating and set a GBX 55 ($0.73) target price on shares of Assura PLC in a report on Tuesday, June 20th.

Assura PLC (AGR) opened at 62.85 on Monday. Assura PLC has a 12 month low of GBX 51.35 and a 12 month high of GBX 67.30. The firm’s market capitalization is GBX 1.04 billion. The stock’s 50 day moving average price is GBX 64.05 and its 200-day moving average price is GBX 62.25.

TRADEMARK VIOLATION NOTICE: “Assura PLC’s (AGR) Buy Rating Reiterated at Liberum Capital” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at

The firm also recently disclosed a dividend, which will be paid on Wednesday, October 18th. Shareholders of record on Thursday, September 14th will be paid a dividend of GBX 0.60 ($0.01) per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a yield of 0.91%.

Assura PLC Company Profile

Assura plc is a United Kingdom-based healthcare real estate investment trust (REIT). The Company is a primary care property investor and developer. The Company develops, invests and manages a portfolio of primary care medical centers across the United Kingdom. The Company’s property portfolio includes Alwoodley Medical Centre, Leeds; Fleetwood Health and Wellbeing Centre, Fleetwood; Frome Medical Practice, Frome; Claremont Medical Centre, Surbiton; Elbury Moor Medical Centre; Grey Gable Surgery; Trellech Surgery; Bewdley Medical Centre; Malmesbury Primary Care Centre, Malmesbury, and Urmston Group Practice, Urmston.

Receive News & Stock Ratings for Assura PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assura PLC and related stocks with our FREE daily email newsletter.